Q4 2022 Financial Results
(April 2022 to March 2023)

APRIL 27, 2023

Agenda

1	**Overall Summary**	• Key Takeaways • FY22 Result
2	**Result**	• Result – YoY, QoQ
3	**Segment Data**	• Digital Solutions Business ・Revenue Growth Rate • Life Sciences Business • Plastics Business
4	**Outlook**	• Summary of FY23 Projection • FY23 Projection • Business Outlook by Segment - FY23 • Market Environment Assumption
5	**Topics**	• DS: Transition of SEMI Fixed Cost • LS: Production Schedule of KBI's New Facility
6	**Management Policy**	• Management Policy: Progress against Strategy
	Appendix	• FY22 Result vs Projection • Overall Statement of P/L • Statement of Financial Position • Statement of Cash Flows • Quarterly Trends by Segments • IR Calendar

***Note**

DS :Digital Solutions business
SEMI :Semiconductor materials
DISP :Display materials
EC :Edge Computing
LS :Life Sciences business
PLA :Plastic business

1. Key Takeaways

Focused on driving profitability improvements during the demand adjustment phase of SEMI market; expect significant profit recovery in FY23 and achievement of the mid-term plan in FY24.

FY22 Result Increase in Revenue Decrease in Profit YoY	• Profit decreased due to deteriorated markets for DISP and PLA and due to special factors in FY21. Revenue and profit increased in SEMI* and LS. • Reflected business restructuring costs of SEMI to the result as Non-Core segment.
FY23 Projection Increase in Revenue & Profit YoY	• Expect significant profit improvements. • LS is driving growth. Expect negative growth in the SEMI market. Pave the way for SEMI's V-shaped recovery in FY24.
Strategic Priorities	• SEMI: Focus on restructuring our business, expand our market share, and strengthening investment for anticipated V-shaped recovery of demand. • LS: Operate KBI's new facility to full capacity in FY23 and execute profitability initiatives. Incorporate the new CRO business by M&A. • Promote operational excellence and margin improvement initiatives, including business restructuring and cost reduction in order to secure long-term growth opportunities and achieve the FY24 mid-term plan.

*Excluding FY21 special factors of Inpria's valuation gain (+7.5bn yen) and impairment loss of cleans facility (-3.8bn yen).

*Please refer to Page 16 and 17 regarding the mid-term policy.

1. Summary : FY22 Result

FY22 Core OP YoY (Bn JPY)

FY22 Act: Revenue 408.9bn、Core OP 34.0bn



Profit decreased due to DISP/PLA and special factors.
For SEMI and LS, profit increased.

Digital Solutions Business	
SEMI	• Both revenue and profit increased in FY22 despite the customers' inventory adjustment in H2 FY22. • Expanded sales for EUV and MOR. Expanded upfront investments.
DISP/ EC	• Both revenue and profit decreased due to deteriorated market, which has been on the recovery trend since October 2022. • The smartphone market deteriorated. EC's market share has expanded.

Life Sciences Business

- Strong sales for MBL's antigen test kits.
- Started commercial production at KBI's the new facility in H2. Completed 13 batches productions as of March 2023.

Plastics Business

- Delay in the auto market recovery. Impacted by price increases of raw materials and fuel.

Adjustments from Core OP to OP (Bn JPY)



Reflected SEMI's business restructuring

Cleans	• Impaired the book value of the US plant to nearly zero due to a decline in earning outlook based on deteriorating business environment. • Downsize the business significantly, including closure of R&D location in the US. • Achieved entry of our new material and will refine the strategy.
Korean sales subsidiary	• Recognized valuation gains on consolidation of our Korean sales subsidiary. • Significantly grow in sales and expand technical services to our Korean customers. • Plan to strengthen local functions in Taiwan and China.

*MOR: Metal Oxide Resist

2. Result – YoY, QoQ

YoY Revenue+, Core OP – (Described in Page 4)

QoQ Revenue-, Core OP -

SEMI : Affected by significant inventory adjustments of customers.
LS: sales timing difference of the antigen test kit.
OTH: Mainly seasonal factors.

(Bn JPY)

		FY21	FY22	YoY	22Q3	22Q4	QoQ
Consolidated	Revenue	341.0	408.9	+20%	115.7	95.9	-17%
	Core Operating Profit	43.3	34.0	-21%	14.6	2.5	-83%
	Operating Profit	43.8	29.4	-33%	14.5	-2.9	-
	Profit, attributable to owners of parent	37.3	15.8	-58%	4.8	-3.8	-
Digital Solutions	Revenue	165.0	170.4	+3%	44.5	35.4	-20%
	Core Operating Profit	39.0	27.8	-29%	8.2	1.1	-87%
	(Core Operating Profit excl. FY21 Special Factors)[*1]	35.3	27.8	-21%	8.2	1.1	-87%
Life Sciences	Revenue	72.5	126.5	+75%	41.6	33.4	-20%
	Core Operating Profit	3.2	8.4	+167%	6.0	1.8	-71%
Plastics	Revenue	90.6	95.8	+6%	26.6	23.6	-11%
	Core Operating Profit	5.3	1.9	-65%	1.4	0.6	-59%
Others/Adjustment	Revenue	12.9	16.2	+25%	3.0	3.6	+18%
	Core Operating Profit	-4.2	-4.1	-	-1.0	-0.9	-
	Exchange rate (USD/JPY)	112	135	+21%	142	132	-7%

	YoY	QoQ
Consolidated	Revenue + Core OP -	Revenue - Core OP -
DS	Revenue + Core OP -	Revenue - Core OP -
SEMI [*1]	Revenue + Core OP +	Revenue - Core OP -
DISP	Revenue - Core OP -	Revenue - Core OP -
EDGE	Revenue - Core OP -	Revenue - Core OP -
LS	Revenue + Core OP +	Revenue - Core OP -
PLA	Revenue + Core OP -	Revenue - Core OP -
OTH	Revenue + Core OP +	Revenue + Core OP +

*1 Excluding FY21 special factors of Inpria's valuation gain (+7.5bn yen) and impairment loss of cleans facility (-3.8bn yen).

*Discontinuing business is not shown on the table, except for Profit, attributable to owners of parent.

3. Segment Data: Digital Solutions Business

(Bn JPY)

	FY21	FY22	YoY	YoY (CER)*	22Q3	22Q4	QoQ	QoQ (CER)*
Revenue	165.0	170.4	+3%	-6%	44.5	35.4	-20%	-18%
Semiconductor materials	110.3	126.4	+15%	+2%	33.0	25.2	-24%	-20%
Display materials	45.9	36.6	-20%	-25%	9.6	8.6	-11%	-9%
Edge computing	8.8	7.5	-16%	-16%	1.9	1.6	-16%	-16%
Core OP	39.0	27.8	-29%	-57%	8.2	1.1	-87%	-76%
Core OP margin	23.6%	16.3%			18.4%	3.1%		
Exchange rate（USD/JPY)	112	135	+21%	0%	142	132	-7%	0%

Core OP analysis

YoY



QoQ



*MOR: Metal Oxide Resist

*Reference data: CER (Constant Exchange Rate. Excluding FX impacts)

3. Digital Solutions Business - Revenue Growth Rate

		YoY ytd	QoQ
Semiconductor materials	EUV	Slightly over +55%	Slightly over +30%
	ArF	Approx. +15%	Slightly over -20%
	Multilayer	Approx. +10%	Slightly Under -30%
	Other Lithography	Approx. +20%	Slightly over -15%
	CMP	Slightly over +20%	Slightly Under -20%
	Cleaner	Approx. +30%	Slightly over -55%
	Packaging	Slightly decreased	Approx. -25%
Display materials	Alignment Films	Approx. -15%	Approx. -20%
	Passivation Coat	Slightly Under -15%	Slightly over +15%
	Color Pigmented Resists	Approx. -65%	Slightly Under -35%
	OLED Materials	Approx. -5%	Slightly decreased
Edge computing	ARTON	Approx. -15%	Slightly over -15%

3. Segment Data：Life Sciences Business

(Bn JPY)

	FY21	FY22	YoY	YoY (CER)*	22Q3	22Q4	QoQ	QoQ (CER)*
Revenue	72.5	126.5	+75%	+58%	41.6	33.4	-20%	-16%
Core OP	3.2	8.4	+167%	+184%	6.0	1.8	-71%	-82%
Core OP margin	4.4%	6.7%			14.4%	5.3%		
Exchange rate（USD/JPY)	112	135	+21%	0%	142	132	-7%	0%

Core OP analysis

YoY

	Revenue	Core Operating Profit
Total	+75%	+167%
CDMO	Approx. +50%	Decrease in OP
CRO	Slightly Under +25%	Same level as FY21
BPM	Approx. +15%	Decrease in OP
IVD	Approx. +200%	Increase in OP

QoQ

	Revenue	Core Operating Profit
Total	-20%	-71%
CDMO	Approx. +5%	Increase in OP
CRO	Approx. -20%	Decrease in OP
BPM	Approx. -15%	Decrease in OP
IVD	Approx. -35%	Decrease in OP

CDMO: Contract Development and Manufacturing Organization of biologics
CRO: Contract Research Organization of pharmaceutical products
BPM: Bioprocess Materials
IVD: In Vitro Diagnostics and Life Science Research

*Reference data: CER (Constant Exchange Rate. Excluding FX impacts)

3. Segment Data：Plastics Business

(Bn JPY)

	FY21	FY22	YoY	YoY (CER)*	22Q3	22Q4	QoQ	QoQ (CER)*
Revenue	90.6	95.8	+6%	+0%	26.6	23.6	-11%	-10%
Core OP	5.3	1.9	-65%	-65%	1.4	0.6	-59%	-59%
Core OP margin	5.9%	1.9%			5.2%	2.4%		
Exchange rate（USD/JPY)	112	135	+21%	0%	142	132	-7%	0%

Core OP analysis

YoY



QoQ



*Reference data: CER (Constant Exchange Rate. Excluding FX impacts)

4. Summary of FY23 Projection

FY22 Result vs FY23 Projection Difference (Bn JPY)

FY23 Pro: Revenue 442bn, Core OP 42bn



Significant profit improvements
LS driving growth
Paving the way for DS' V-shaped recovery in FY24

Digital Solutions Business

SEMI	• Sales nearly flat, profit down on increased investment. • Project negative growth of SEMI market for the full year despite the market recovery expected in H2. • Take initiatives for FY24 (business restructuring, EUV/MOR investment, business augmentation in Asia) • Market share in key materials remained stable. Increased share in advanced fields.
DISP/EC	• Anticipate increased revenue and profit. • Expect stable recovery in the FPD panel market. • Expand market share of optical IPS and OLED materials. • Factor in EC's market share increase.

Life Sciences Business

- Expand KBI's profit growth toward H2. The new plant will be in full production in H2 FY23. Launched a restructuring project to achieve 20% OP margin in FY24.
- Include confirmed orders of MBL's antigen test kits.
- Incorporated the new biobank business in CRO through M&A.

Plastics Business

- Expect recovery of the auto market.
- Expect improved trading spread with revision of sales price.

*MOR: Metal Oxide Resist

4. FY23 Projection

<Revised on April 27, 2023>

(Bn JPY)

		FY22 Act	FY23 Pro	FY22 vs FY23 Pro YoY
Consolidated	Revenue	408.9	442.0	+8%
	Core Operating Profit	34.0	42.0	+23%
	Operating Profit	29.4	42.0	+43%
	Profit, attributable to owners of parent	15.8	25.0	+58%
Digital Solutions	Revenue	170.4	175.0	+3%
	Semiconductor materials	126.4	126.0	-0%
	Display materials	36.6	40.0	+9%
	Edge computing	7.5	9.0	+21%
	Core Operating Profit	27.8	27.0	-3%
Life Sciences	Revenue	126.5	142.5	+13%
	CDMO	-	70.0	
	CRO	-	31.5	
	BPM	-	5.5	
	IVD	-	35.5	
	Core Operating Profit	8.4	16.0	+89%
Plastics	Revenue	95.8	107.5	+12%
	Core Operating Profit	1.9	4.0	+116%
Others/ Adjustment	Revenue	16.2	17.0	+5%
	Core Operating Profit	-4.1	-5.0	+23%
Exchange rate (USD/JPY)*3		135	135	-0%

(Bn JPY)

	FY22 Act	FY23 Pro	FY22 vs FY23 Pro YoY
Depreciation*1	28.4	32.0	3.6
CAPEX *2	44.2	37.0	-7.2
RD expenses	27.0	30.0	3.0

*1 Including IFRS16 lease asset depreciation for FY22 Act and FY23 Pro. If excluded, FY22 Act is 25.4bn Yen.
*2 Inspection basis
*3 Exchange rate FY23 Pro is based on the current estimated rate. Exchange rate impact is expected to be approx. 500 million yen per weaker 1 yen.
*Discontinuing business is not shown on the table except for Profit, attributable to owners of parent.

CDMO: Contract Development and Manufacturing Organization of biologics
CRO: Contract Research Organization of pharmaceutical products
BPM: Bioprocess Materials
IVD: In Vitro Diagnostics and Life Science Research

4. Business Outlook by Segment - FY23

	FY23 Outlook	Demand Environment H1	Demand Environment H2	FY24 Outlook
SEMI	**Adjustment in near-term. Focused on initiatives to expand our market share, strengthen investments, and restructure our business for V-shaped growth after demand recovery.** • Our market share of EUV increased (3 nm and beyond, DRAM). MOR started up well. Other materials also have strong competitive positions. • Upfront investments such as EUV/MOR will continue, but FY23 will be the peak. Investment range is expected to decrease in FY24. • Downsize our Cleans business in US significantly. But no change to SEMI business growth expectation. For other structural reforms, we will execute initiatives including consolidation of locations and operations in Asia.	↘	↗	↗
DISP	**Market recovers, revenue and profit increase.** • Expect market recovery trend to continue with profitability improvements. • Assured to expand our market shares for optical IPS and OLED materials. Factored in our FY23 revenue and profit growth expectations.	↗	↗	↗
EC	• Expect market recovery to be slow. • Achieved to increase our market share. Make sure to execute cost reductions to improve profitability.	→	↗	↗
LS	**Robust demand. Further contribution from KBI's operation expansion.** • Complete repairs of KBI's Colorado facility in May. Expand operations of KBI's new facility toward H2 FY23 and contribute to the growth with full-capacity operation full year toward FY24. Execute business restructuring for profitability improvement to 20% OP margin in FY24. • Include confirmed orders of MBL's antigen test kits. • Expect partial slowdown in demand for CRO but expect to continue growth with new CRO business added to the portfolio.	→	↗	↗
PLA	• Expect sales increase due to auto production recovery. Trading spread will improve.	↗	→	↗
OTH	• Aim to maintain at same level as FY22. Accelerate DX investments. • Review all product lines of each segment from a profitability perspective			

*MOR Metal oxide resist

4. Market Environment Assumption

	FY22Act	FY23 Outlook	FY24 Outlook
FX（USD/JPY)	135	135	-
Silicon Wafer Input (YoY)	+/-0%	-5%	+14%
Panel Makers Utilization Rate Panel Production (YoY)	71% -19%	78% +12%	83% +8%
Smartphone Shipments (YoY)	-9%	+3%	+4%
Global Automobile Production (YoY)	+8%	+5%	+4%
Bio Pharmaceutical Market (YoY)	+8%	+7%	+9%

*JSR estimates based on resources of outside research institutions.

5. DS: Transition of SEMI Fixed Cost

(Bn JPY)



*Excluding FY21 special factors of Inpria's valuation gain (+7.5bn yen) and impairment loss of cleans facility (-3.8bn yen).
*Based on CER (Constant Exchange Rate. Excluding FX impacts)

*MOR Metal oxide resist

5. LS: Production Schedule of KBI's New Facility

New facility in North Carolina: Expected to Achieve Full Utilization through Q4 FY23

of batch started in each Q/Utilization



KBI: Profitability Initiatives Expand Sales and Strengthen Cost Control



*The above production plan is subject to change as it is reviewed from time to time. No major changes from previous disclosure.

*As of April 2023.

6. Management Policy

JSR

Vision

- Create value for all stakeholders through **sustainable** growth
- Strengthen our **resilient** business structure by responding to changes in the environment

Business Portfolio

the center of our business portfolio

Digital Solutions ✕ **Life Sciences**

(especially **SEMI**)

- **SEMI**
  Growth exceeding market growth. Scale and fields expansion including M&A.
- **DISP**
  Optimize our business structure and transition to profit growth.

- Revenue: more than 100bn yen, ROS: 20%
- Strengthen the strategic link among Life Sciences groups for sustainable growth.

Business Target (FY24)

ROE

More than **10**%

Core OP

Exceed Prior Peak

more than 60bn yen
Digital Solutions &
Life Sciences

Structure

Resilient infrastructure

Innovation

Digitalization

ESG commitment

Employee engagement

6. Management Policy : Progress against Strategy

JSR

		Progress
Vision	Business Portfolio	• Focus strategic investments on our core businesses following completion of the transfer of the Elastomers business on April 1, 2022. • Made a new acquisition in the CRO field in December 2022. In SEMI field investment, acquisition of Inpria progressed in FY21.
	Business Target (FY24)	• No change in target: Expect to achieve FY24 target with OP exceeding 60bn yen (record) and target more than 10% ROE. • Ensure to improve profitability, targeting 23% OP margin for DS and 20% OP margin for LS. • Reinforce business foundations in response to short-term slow down in demand.
	Organization	• Set sustainability KPIs. Reduce GHG emissions, improve employee engagement, and promote DE&I measures. • Continue to focus on key strategic investments and those for future profitability including DX etc.
	Capital Allocation	• Implemented a dividend increase of 60 yen to 70 yen and share buybacks of approx. 30bn yen in FY22. • No change to capital allocation policy. Currently focusing on improving operating CF.

Business Strategy

Digital Solutions Business	• Expand EUV market share in advanced Logic application. MOR business has been progressing well, with integration of Inpria progressing. • In SEMI, laid the foundation for mid-term market share expansion and accelerated development of EUV and MOR segments. Continued to improve sales and technical support capabilities (Taiwan, China, South Korea, etc.). Downsize and restructure Cleans business. • Completed integration and optimization in DISP. The market continues to recover. Focus remains on developing new materials such as OLEDs. • Promote measures to improve profitability including cost reductions in response to short-term slow down in demand.
Life Sciences Business	• Continue to focus expansion of operations at KBI's new facility, expected to be significant profit growth driver for FY23. this will be a growth driver for FY24 as well. • Achieved revenue target of 100bn yen in FY22. Focus on achieving steady revenue growth, and taking intensive actions to improve efficiency toward 20% OP margin target. • Expanded CRO business portfolio. Strengthen our LS business by promoting our uniqueness.

*MOR: Metal Oxide Resist

Appendix: FY22 Result vs Projection

(Bn JPY)

		FY22 Act	FY22 Pro (as of Feb.6)	Act vs Pro +/-
Consolidated	Revenue	408.9	411.0	-2.1
	Core Operating Profit	34.0	34.0	0.0
	Operating Profit	29.4	34.5	-5.1
	Profit, attributable to owners of parent	15.8	24.0	-8.2
Digital Solutions	Revenue	170.4	170.5	-0.1
	Semiconductor materials	126.4	127.0	-0.6
	Display materials	36.6	36.0	0.6
	Edge computing	7.5	7.5	-0.0
	Core Operating Profit	27.8	28.0	-0.2
Life Sciences	Revenue	126.5	129.0	-2.5
	Core Operating Profit	8.4	9.0	-0.6
Plastics	Revenue	95.8	96.0	-0.2
	Core Operating Profit	1.9	1.8	0.1
Others/ Adjustment	Revenue	16.2	15.5	0.7
	Core Operating Profit	-4.1	-4.8	0.7
	Exchange rate (USD/JPY)*3	135	135	0.5

(Bn JPY)

	FY22 Act	FY22 Pro (as of Feb.6)	Act vs Pro +/-
Depreciation ＊1	28.4	23.5	4.9
CAPEX ＊2	44.2	36.0	8.2
RD expenses	27.0	25.5	1.5

*1 Including IFRS16 lease asset depreciation for FY22 Act. If excluded, FY22 Act is 25.4bn Yen.
*2 Inspection basis
*3 Exchange rate impact is expected to be approx. 500 million yen per weaker 1 yen.

Appendix: Overall Statement of P/L

(Bn JPY)

	FY21	FY22	YoY
Revenue	341.0	408.9	+20%
Cost of sales	214.9	265.8	+24%
Gross profit	126.1	143.1	+14%
Selling, general and administrative expenses	87.3	109.8	+26%
Other operating income/expenses	4.9	-4.0	-
Share of profit of investments accounted for using equity method	0.2	0.1	-47%
Operating Profit	43.8	29.4	-33%
Finance income/cost	1.8	0.5	-73%
Income taxes	8.4	13.4	+60%
Profit from continuing business	37.2	16.4	-56%
Profit from discontinued business	2.3	-	-
Profit	39.4	16.4	-58%
Profit, attributable to owners of parent	37.3	15.8	-58%
Profit, attributable to non-controlling interests	2.1	0.6	-70%

	FY21	FY22	YoY
EPS(JPY)	173.49	75.56	-56%
EPS - continuing business	162.52	75.56	-54%
EPS - discontinued business	10.97	–	-

	FY21	FY22	YoY
Exchange rate(USD/JPY)	112	135	+21%

Breakdown from Core OP to OP

(Bn JPY)

	FY21	FY22
Core Operating Profit	43.3	34.0
Partial Reduction of Impairment	1.3	-
Gain on sales of shares of subsidaries and affiliates	0.3	-
Business structural reform expenses	-	-9.0
Gain on step acquisitions	-	3.4
Loss on valuation of fixed assets	-	-0.2
Loss on valuation of investments in subsidiaries	-1.4	-
Loss on valuation of capital investments in subsidiaries	-	1.0
Others	0.2	0.1
Operating Profit	43.8	29.4

Appendix: Statement of Financial Position

(Bn JPY)

	22/3E	23/3E	+/-
Current assets	437.0	299.3	-137.7
Cash and cash equivalents	45.6	72.6	27.1
Trade and other receivables	76.1	78.8	2.7
Inventories	104.9	118.4	13.5
Others	19.1	29.4	10.3
Non-current Assets held for sale	191.3	0.0	-191.3
Non-current assets	372.4	415.3	42.9
Property, plant and equipment	159.5	169.6	10.1
Goodwill	117.6	152.9	35.2
Other intangible assets	24.6	27.8	3.2
Others	70.6	65.0	-5.6
Total Assets	809.4	714.6	-94.8
Current liabilities	288.3	181.8	-106.5
Trade and other payables	63.5	79.6	16.1
Bonds and borrowings	69.2	62.5	-6.7
Others	40.0	39.6	-0.3
Non-current liabilities held for sale	115.6	0.0	-115.6
Non-current liabilities	106.4	151.9	45.5
Bonds and borrowings	48.7	95.7	46.9
Others	57.6	56.2	-1.5
Total Liabilities	394.6	333.6	-61.0
Equity attributable to owners of parent	376.0	355.5	-20.5
Non-controlling interests	38.7	25.4	-13.3
Total Equity	414.7	380.9	-33.8

*Including both continuing business and discontinued business

Capital policy Topics for FY22

- Share buybacks: approx. 30bn yen
- Cancellation of Treasury Stock: approx. 17.7M shares (8% of total # of shares issued before cancelation)
- Dividend paid: approx. 15bn yen (Increased in FY21)
- Bond issued: approx. 25bn yen
- Income related to business transfer: approx. 50bn yen
- Capex, etc.

Net Debt

(Cash and cash equivalents – Debt with interest)

2022/3 E : approx.72bn JPY
2023/3E: approx. 86bn JPY

Equity ratio

(Equity attributable to owners of parents)

2022/3 E : 46.5%
2023/3 E : 49.8%

Basic capital allocation policy

1. Invest in future business growth, including M&A (mainly in SEMI and LS)
2. Maintaining a strong financial position that can flexibly respond to business investments
3. Shareholder return (50% as a guideline)

Appendix: Statement of Cash Flows

(Bn JPY)

	FY21	FY22	YoY +/-
Cash flows from operating activities	18.3	29.3	11.0
Income before income taxes	48.9	29.8	-19.0
Depreciation and amortization	22.5	28.4	5.9
Change in working capital	-48.9	-8.4	40.5
Others	-4.2	-20.6	-16.4
Cash flows from investment activities	-63.1	-4.0	59.1
Purchase of tangible and intangible assets	-46.8	-28.8	18.1
Acquisition of shares of subsidiaries	-47.3	-23.1	24.2
Sales of shares of subsidaries and affiliates	15.2	51.2	36.0
Others	15.9	-3.3	-19.2
FCF	-44.8	25.2	70.1
Cash flows from financing activities	23.0	-15.2	-38.2
Change in treasury stock	0.0	-30.1	-30.1
Cash dividends paid	-15.1	-15.6	-0.5
Others	38.1	30.5	-7.6
Effect of exchange rate changes on cash and cash equivalents	-1.5	0.6	2.2
Increase (decrease) in cash and cash equivalents	-23.4	10.6	34.0
Cash and cash equivalents at beginning of period	85.4	45.6	-39.8
Cash and cash equivalents included in assets held for sale	-16.4	16.4	32.8
Cash and cash equivalents at end of period	45.6	72.6	27.1

Appendix: Quarterly Trends by Segments

(Bn JPY)

		21Q1	21Q2	21Q3	21Q4	FY21	22Q1	22Q2	22Q3	22Q4	FY22	Q4 YoY	Q4 YoY (CER)*	FY YoY	FY YoY (CER)*
Consolidated	Revenue	82.3	85.9	88.4	84.4	341.0	93.3	104.0	115.7	95.9	408.9	+14%	+7%	+20%	+10%
	Core Operating Profit	12.6	10.5	19.2	1.0	43.3	6.2	10.7	14.6	2.5	34.0	+147%	+76%	-21%	-46%
	Operating Profit	11.1	11.7	19.2	1.7	43.8	7.3	10.4	14.5	-2.9	29.4	-272%	-	-33%	-
	Profit, attributable to owners of parent	8.2	9.4	17.8	1.9	37.3	5.7	9.0	4.8	-3.8	15.8	-299%	-	-58%	-
Digital Solutions	Revenue	39.3	41.3	42.7	41.7	165.0	42.9	47.7	44.5	35.4	170.4	-15%	-21%	+3%	-6%
	Semiconductor materials	26.1	26.8	29.2	28.2	110.3	30.5	37.7	33.0	25.2	126.4	-11%	-17%	+15%	+2%
	Display materials	11.1	12.5	11.0	11.3	45.9	10.4	8.0	9.6	8.6	36.6	-24%	-27%	-20%	-25%
	Edge computing	2.1	2.1	2.5	2.2	8.8	2.0	2.0	1.9	1.6	7.5	-28%	-28%	-16%	-16%
	Core Operating Profit	10.4	9.1	16.7	2.7	39.0	7.7	10.8	8.2	1.1	27.8	-59%	-113%	-29%	-57%
	Core Operating Profit Margin	27%	22%	39%	6%	24%	18%	23%	18%	3%	16%	-	-	-	-
Life Sciences	Revenue	16.3	17.4	19.6	19.1	72.5	22.7	28.7	41.6	33.4	126.5	+75%	+62%	+75%	+58%
	Core Operating Profit	1.2	0.8	1.9	-0.7	3.2	0.0	0.7	6.0	1.8	8.4	-362%	-296%	+167%	+184%
	Core Operating Profit Margin	7%	4%	10%	-4%	4%	0%	2%	14%	5%	7%	-	-	-	-
Plastics	Revenue	23.8	24.0	22.9	19.9	90.6	22.8	22.9	26.6	23.6	95.8	+18%	+14%	+6%	+0%
	Core Operating Profit	1.9	1.6	1.6	0.3	5.3	-0.5	0.4	1.4	0.6	1.9	+110%	+110%	-65%	-65%
	Core Operating Profit Margin	8%	7%	7%	1%	6%	-2%	2%	5%	2%	2%	-	-	-	-
Others/Adjustment	Revenue	2.9	3.2	3.2	3.6	12.9	4.9	4.7	3.0	3.6	16.2	-0%	-0%	+25%	+25%
	Core Operating Profit	-0.9	-1.0	-1.0	-1.3	-4.2	-1.0	-1.2	-1.0	-0.9	-4.1	-27%	-121%	-3%	-106%
	Exchange rate (USD/JPY)	109	110	114	116	112	130	138	142	132	135	+14%	0%	+21%	0%

*Core OP is calculated by excluding profit or loss caused by non-recurring factors from OP.
*Discontinuing business is not shown on the table, except for Profit, attributable to owners of parent.
*FY21 includes Inpria's valuation gain of +7.5bn yen and Cleans' impairment loss of -3.8 bn yen.

Appendix: IR Calendar

Announcement of Earnings Results

Q1 FY23	August 7, 2023

*Please note that the above is subject to change.

NB: The forecasts, future plans and strategies made in this document contain a variety of uncertain factors since it has been prepared based on judgments from information that is currently available. Actual business results may differ from those projected, depending on factors such as the economic status of the market surrounding the company.